{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:52:46Z","timestamp":1781610766056,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Youth Independent Innovation Science Fund Project of the PLA General Hospital","award":["22QNFC134"],"award-info":[{"award-number":["22QNFC134"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400130"],"award-info":[{"award-number":["82400130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation Pre-Research Project of the Second Medical Center of the PLA General Hospital","award":["YYM2412"],"award-info":[{"award-number":["YYM2412"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The relationships of renal function with linezolid trough concentration (C\n                      <jats:sub>min<\/jats:sub>\n                      ) and hematological toxicity have not been clarified in elderly patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this propensity-matched cohort analysis, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and March 2024 were included. The patients were grouped by renal function and propensity score matching (PSM) was used to balance baseline characteristics. Linezolid C\n                      <jats:sub>min<\/jats:sub>\n                      and hematological indices were monitored dynamically.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 320 patients, 152 were eventually enrolled after PSM, including 56 (36.8%) patients with normal renal function (RN) and 96 (63.2%) patients with renal dysfunction (RD). C\n                      <jats:sub>min<\/jats:sub>\n                      at 3\u20135 (12.5\u00a0mg\/L vs. 21.2\u00a0mg\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001) and 6\u201310 days (14.8\u00a0mg\/L vs. 27.4\u00a0mg\/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090001) was significantly lower in the RN group. The risk of linezolid-associated thrombocytopenia (LAT) and linezolid-associated anemia (LAA) in the RD group was 4.485 folds and 2.308 folds higher than in the RN group. The decreases in hematological indices were significantly higher in RD group than in RN group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Renal function significantly affected linezolid C\n                      <jats:sub>min<\/jats:sub>\n                      and hematological toxicity, and the dose of linezolid should be reduced in elderly patients with renal dysfunction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ChiCTR2100045707; Registration Date: 23\/04\/2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-025-06241-9","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:20:58Z","timestamp":1754482858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Bing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrui","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"1","key":"6241_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","volume":"42","author":"GG Rao","year":"2020","unstructured":"Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83\u201392. https:\/\/doi.org\/10.1097\/FTD.0000000000000710.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"6241_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jsps.2019.09.002","volume":"27","author":"A Alsultan","year":"2019","unstructured":"Alsultan A. Determining therapeutic trough ranges for linezolid. Saudi Pharm J. 2019;27(8):1061\u20133. https:\/\/doi.org\/10.1016\/j.jsps.2019.09.002. Epub 2019 Sep 25. PMID: 31885465; PMCID: PMC6921164.","journal-title":"Saudi Pharm J"},{"issue":"3","key":"6241_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","volume":"44","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.010.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"6241_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40262-020-00964-1","volume":"60","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Fusi M, Cozzi V, Baldelli S, Bonini I, Gervasoni C, Clementi E. Supra-therapeutic linezolid trough concentrations in elderly patients: a call for action?? Clin Pharmacokinet. 2021;60(5):603\u20139. https:\/\/doi.org\/10.1007\/s40262-020-00964-1.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"6241_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00228-017-2303-6","volume":"73","author":"M Tinelli","year":"2017","unstructured":"Tinelli M, Gervasoni C, Piazza M, Terzi R, Cozzi V, Maffezzini E, Cerri C, Castoldi S, Baldelli S, Cattaneo D. Is it time to revise linezolid dose in elderly patients? Eur J Clin Pharmacol. 2017;73(10):1335\u20136. https:\/\/doi.org\/10.1007\/s00228-017-2303-6. Epub 2017 Jul 15. PMID: 28712044.","journal-title":"Eur J Clin Pharmacol"},{"key":"6241_CR6","doi-asserted-by":"publisher","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin B, Hu Y, Xu P, Xu T, Chen C, He L, Zhou M, Chen Z, Zhang C, Yu X, Fang L, Zhu J, Ji Y, Lin Q, Cao H, Dai Y, Lu X, Shi C, Li L, Wang C, Li X, Fang Q, Miao J, Zhu Z, Lin G, Zhan H, Lv S, Zhu Y, Cai X, Ying Y, Chen M, Xu Q, Zhang Y, Xu Y, Federico P, Jiang S, Dai H. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022;10:967311. https:\/\/doi.org\/10.3389\/fpubh.2022.967311. PMID: 36033811; PMCID: PMC9399604.","journal-title":"Front Public Health"},{"issue":"8","key":"6241_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae188","volume":"79","author":"T Liu","year":"2024","unstructured":"Liu T, Yuan Y, Wang C, Wu J, Wang Y, Na P, Chen X, Rao W, Zhao J, Wang D, Wang H, Duan Z, Xie F, Fang X, Xie L, Li H. Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study. J Antimicrob Chemother. 2024; dkae188. https:\/\/doi.org\/10.1093\/jac\/dkae188.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"6241_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/atm.2020.03.207","volume":"8","author":"J Fang","year":"2020","unstructured":"Fang J, Chen C, Wu Y, Zhang M, Zhang Y, Shi G, Yao Y, Chen H, Bian X. Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study. Ann Transl Med. 2020;8(7):493. https:\/\/doi.org\/10.21037\/atm.2020.03.207. PMID: 32395537; PMCID: PMC7210126.","journal-title":"Ann Transl Med"},{"issue":"1","key":"6241_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","volume":"22","author":"H Kawasuji","year":"2021","unstructured":"Kawasuji H, Tsuji Y, Ogami C, Kimoto K, Ueno A, Miyajima Y, Kawago K, Sakamaki I, Yamamoto Y. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol. 2021;22(1):13. https:\/\/doi.org\/10.1186\/s40360-021-00479-w. PMID: 33663616; PMCID: PMC7934392.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"10","key":"6241_CR10","doi-asserted-by":"publisher","first-page":"e00687","DOI":"10.1128\/AAC.00687-17","volume":"61","author":"A Galar","year":"2017","unstructured":"Galar A, Valerio M, Mu\u00f1oz P, Alcal\u00e1 L, Garc\u00eda-Gonz\u00e1lez X, Burillo A, Sanjurjo M, Grau S, Bouza E. Systematic therapeutic drug monitoring for linezolid: variability and clinical impact. Antimicrob Agents Chemother. 2017;61(10):e00687\u201317. https:\/\/doi.org\/10.1128\/AAC.00687-17. PMID: 28739788; PMCID: PMC5610525.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"6241_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcpt.12797","volume":"121","author":"F Pea","year":"2017","unstructured":"Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121(4):303\u20138. https:\/\/doi.org\/10.1111\/bcpt.12797.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"6241_CR12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","volume":"48","author":"D Cattaneo","year":"2016","unstructured":"Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48(6):728\u201331. Epub 2016 Oct 12. PMID: 27769709.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"6241_CR13","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","volume":"68","author":"Y Nukui","year":"2013","unstructured":"Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128\u201333. https:\/\/doi.org\/10.1093\/jac\/dkt133.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"6241_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","volume":"17","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382\u20137. https:\/\/doi.org\/10.1007\/s10156-010-0182-1.","journal-title":"J Infect Chemother"},{"issue":"9","key":"6241_CR15","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiac.2022.05.004","volume":"28","author":"I Maray","year":"2022","unstructured":"Maray I, Rodr\u00edguez-Ferreras A, \u00c1lvarez-Asteinza C, Alaguero-Calero M, Valledor P, Fern\u00e1ndez J. Linezolid induced thrombocytopenia in critically ill patients: risk factors and development of a machine learning-based prediction model. J Infect Chemother. 2022;28(9):1249\u201354. Epub 2022 May 14. PMID: 35581121.","journal-title":"J Infect Chemother"},{"issue":"1","key":"6241_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijantimicag.2008.07.002","volume":"33","author":"K Matsumoto","year":"2009","unstructured":"Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K, Shimodozono Y, Yamada K, Ikawa K, Morikawa N. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents. 2009;33(1):98\u20139. Epub 2008 Sep 14. PMID: 18790615.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"6241_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ejhpharm-2022-003258","volume":"31","author":"Y Qin","year":"2024","unstructured":"Qin Y, Chen Z, Gao S, Shen Y, Ye Y. Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients. Eur J Hosp Pharm. 2024;31(2):94\u2013100. https:\/\/doi.org\/10.1136\/ejhpharm-2022-003258.","journal-title":"Eur J Hosp Pharm"},{"issue":"8","key":"6241_CR18","doi-asserted-by":"publisher","first-page":"e00605","DOI":"10.1128\/AAC.00605-19","volume":"63","author":"RL Crass","year":"2019","unstructured":"Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother. 2019;63(8):e00605\u201319. https:\/\/doi.org\/10.1128\/AAC.00605-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"6241_CR19","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/jac\/dkad191","volume":"78","author":"J Xu","year":"2023","unstructured":"Xu J, Lu J, Yuan Y, Duan L, Shi L, Chen F, Cao Y, Xu G, Feng Z, Li L, Xue H, Sun J, Zhou Q, Zhuang Z, Tang L. Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2023;78(8):1974\u201381. https:\/\/doi.org\/10.1093\/jac\/dkad191.","journal-title":"J Antimicrob Chemother"},{"key":"6241_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117704","volume":"554","author":"H Brozmanov\u00e1","year":"2024","unstructured":"Brozmanov\u00e1 H, \u0160i\u0161t\u00edk P, \u010euricov\u00e1 J, Kac\u00ed\u0159ov\u00e1 I, Ka\u0148kov\u00e1 K, Kolek M. Liquid chromatography-tandem mass spectrometry methods for quantification of total and free antibiotic concentrations in serum and exudate from patients with post-sternotomy deep sternal wound infection receiving negative pressure wound therapy. Clin Chim Acta. 2024;554: 117704. https:\/\/doi.org\/10.1016\/j.cca.2023.117704.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"6241_CR21","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"6241_CR22","doi-asserted-by":"publisher","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","volume":"51","author":"AP MacGowan","year":"2003","unstructured":"MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):ii17\u201325. https:\/\/doi.org\/10.1093\/jac\/dkg248.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"6241_CR23","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","volume":"47","author":"ME Brier","year":"2003","unstructured":"Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O\u2019Grady M, Hopkins NK, Jungbluth GL. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775\u201380. https:\/\/doi.org\/10.1128\/AAC.47.9.2775-2780.2003. PMID: 12936973; PMCID: PMC182634.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06241-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-06241-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06241-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:08:29Z","timestamp":1781608109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-025-06241-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6241"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-06241-9","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Chinese PLA General Hospital (Ethical approval number: S2020-206\u201301), and written informed consent was obtained from all the participants or legal agents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"597"}}